{
    "relation": [
        [
            "Company",
            "VERISK ANAL\u2026",
            "ZOE'S KITCH\u2026",
            "EURONET WOR\u2026",
            "GTT COMMUNI\u2026",
            "MITEK SYSTE\u2026"
        ],
        [
            "Symbol",
            "VRSK",
            "ZOES",
            "EEFT",
            "GTT",
            "MITK"
        ],
        [
            "Price",
            "78.60",
            "43.55",
            "68.27",
            "23.64",
            "3.56"
        ],
        [
            "%Chg",
            "+7.32%",
            "+5.35%",
            "+5.24%",
            "+3.64%",
            "+3.49%"
        ]
    ],
    "pageTitle": "Eli Lilly Scraps a Phase III Study - December 17, 2012 - Zacks.com",
    "title": "",
    "url": "http://www.zacks.com/stock/news/88698/eli-lilly-scraps-a-phase-iii-study",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 0,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987174.71/warc/CC-MAIN-20150728002307-00181-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 844199535,
    "recordOffset": 844176537,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{14869=by Zacks Equity Research \u00a0\u00a0Published on December 17, 2012 |, 63649=At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm., 63588=Copyright \u00a9 2015 Zacks Investment Research, 21689=Eli Lilly said that two other phase III studies with tabalumab in the rheumatoid arthritis program will continue. These studies are being conducted in different patient populations \u2013 the company said that it will not enroll new patients in the rheumatoid arthritis program unless additional analysis of these studies is completed in early 2013. Tabalumab is also being evaluated in an open-label extension study and other smaller studies., 22337=Eli Lilly expects a post-tax charge of 2 cents in the fourth quarter of 2012 due to the discontinuation of the FLEX-M study.}",
    "lastModified": "Thu, 30 Jul 2015 07:21:32 -0500",
    "textBeforeTable": "Income Momentum Value Growth Zacks #1 Rank Top Movers for Jul 30, 2015 Zacks #1 Rank Top Movers Zacks #1 Rank Top Movers for 07/30/15 } } document.getElementById('score_val').className = ''; document.getElementById('score_val').innerHTML = ''; document.getElementById('tab_label').innerHTML = tab_text; { else } document.getElementById('score_val').className = 'scores_val'; document.getElementById('score_val').innerHTML = 'A'; document.getElementById('tab_label').innerHTML = tab_text+ ' Score'; { if(tab_text != 'income') document.getElementById('rank_text').innerHTML = cat_uri; var cat_uri = 'View All Zacks Rank #1 '+tab_text+' Stocks'; var cat_uri = '/stocks/buy-list/'+tab_text; { function footer_text(tab_text)",
    "textAfterTable": "Company Symbol Price %Chg ACCO BRANDS\u2026 ACCO 8.04 +11.82% ITT EDUCATI\u2026 ESI 5.67 +10.10% TRINITY IND\u2026 TRN 29.79 +4.82% CAPSTONE MI\u2026 CSFFF 0.74 +4.33% CELESTICA I\u2026 CLS 13.45 +3.86% Company Symbol Price %Chg TEEKAY TANK\u2026 TNK 7.30 +3.55% BJ'S RESTAU\u2026 BJRI 51.08 +1.57% COTT CORP Q\u2026 COT 10.39 +0.97% A O SMITH C\u2026",
    "hasKeyColumn": true,
    "keyColumnIndex": 1,
    "headerRowIndex": 0
}